Drug Type Monoclonal antibody |
Synonyms |
Target |
Mechanism LIF antagonists(Leukemia inhibitory factor antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization- |
Active Organization- |
Inactive Organization |
Drug Highest PhaseClinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Malignant Solid Neoplasm | Phase 2 | US | 21 May 2018 | |
Advanced Malignant Solid Neoplasm | Phase 2 | ES | 21 May 2018 | |
Advanced Malignant Solid Neoplasm | Phase 2 | CA | 21 May 2018 | |
Non-Small Cell Lung Cancer | Phase 2 | US | 21 May 2018 | |
Ovarian Cancer | Phase 2 | US | 21 May 2018 | |
Ovarian Cancer | Phase 2 | ES | 21 May 2018 | |
Ovarian Cancer | Phase 2 | CA | 21 May 2018 | |
Pancreatic Cancer | Phase 2 | ES | 21 May 2018 | |
Pancreatic Cancer | Phase 2 | CA | 21 May 2018 | |
Pancreatic Cancer | Phase 2 | US | 21 May 2018 |
NCT03490669 (AACR2020) Manual | Phase 1 | 41 | (14 in dose escalation; 27 in expanded cohorts) | (jhvnpuzwoj) = lpjuwjerzp eencmxxxng (lymyhxerii ) View more | Positive | 15 Aug 2020 | |
Phase 1 | 41 | (iaxcpmcojo) = 38 AEs (30 grade (Gr) 1,7 Gr 2, and 1 Gr 3), reported as possibly related to MSC-1 dpitgvmzsw (fhqrigiqht ) | - | 30 Sep 2019 |